VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.
VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor and it can be readily adapted to target a wide range of cancer-related antigens.
The Company has a pipeline of complementary development candidates targeting different tumor structures.
Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer.
VAXIMM has an ongoing clinical trial evaluating VXM01 in combination with the human anti-PD-L1 antibody, avelumab, as part of a scientific collaboration with Merck KGaA, Darmstadt, Germany
VAXIMM also has a neoantigen program currently in preclinical development; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a strategic clinical trial collaboration with NEC Corporation for the development of personalized neoantigen cancer vaccines.
The Company also has entered into a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs.
VAXIMM’s investors include BB Biotech Ventures, BCM Europe, BioMed Partners, CMS, M Ventures, NEC and Sunstone Capital.
With VAXIMM’s highly adaptable platform, a COVID-19 vaccine development project has recently been initiated.
VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities.
VAXIMM has a strong management team of experienced leaders with outstanding scientific knowledge and medical development expertise.
Thomas D. Szucs is Professor and Director of the Institute for Pharmaceutical Medicine at the University of Basel, Switzerland. His research and teaching activity is focused on the areas of pharmacoeconomics, pharmaceuticals policy, healthcare provision research and healthcare technology assessment. He previously served as Head of Health Economics at the Institute of Social and Preventive Medicine of the University of Zurich. Positions he held in the past include the following: Head of Research and founder of the Pharmaeconomics Centre at the University of Milan, Italy; Head of the working group for clinical economics at the University of Munich, Germany; Senior Consultant at Arthur D. Little, Inc.; and Head of the Health Economics Department at Hoffmann-La Roche AG in Basel, Switzerland. Prof. Szucs is also a member of the editorial team of various specialist scientific journals.
After studying medicine and completing his doctorate at the University of Basel, Thomas D. Szucs obtained a Master's degree in business studies from the University of St. Gallen, a Master in public health at Harvard University and a LL.M. in international commercial law at the University of Zurich. He is a specialist recognised by the Swiss Medical Association (FMH) for pharmaceutical medicine, prevention and healthcare. In 2010 he became honorary professor at the University of Peking Health Sciences Centre.
Prior to joining MPM in 2002, he was at Roche, where he served for nearly 20 years in several senior management positions in the global Pharma R&D organization, including VP and Director of the International Pharma Research Strategy Unit and Chief of Staff to the President of Roche Global R&D. He organized and served on the Global Board of R&D Directors and the Pharma Portfolio Board. Most recently he was VP and CSO of Genetics and Integrated Medicine and a member of the Roche Genetics Executive Committee.
Dr. Hosang received his M.S. and Ph.D. degrees in Biochemistry from the ETH in Zurich, and pursued his postgraduate training at Stanford University Medical School and at the University of Washington in Seattle. He currently serves as the Chairman of the Board of Directors of Unitectra AG, the joint technology transfer office of the Universities of Zurich, Bern and Basel.